References
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
- Musto P, Maurillo L, Spagnoli, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes. Cancer 2010; 116: 1485–1494.
- Wijermans P, Lubbert M, Verhoef G, et al. low-dose 5tAza-2’-Deoxycitidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956–962.
- Merkem D, Filanovsky K, Gafter-Gvili A, et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: retrospective multicenter study. Am J Hematol 2013; 88: 130–134.
- Falantes JF, Calderon C, Marquez-Malaver FJ, et al. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk 2014; 14: 80–86.
- Toma A, Fenaux P, Dreyfus F, et al. Infections in myelodysplastic syndromes. Haematologica 2012; 97: 1459–1469.
- National Comprehensive Cancer Network. NCCN guidelines for supportive care: prevention and treatment of cancer-related infections, version 1, 2013. Available from: http:/www.nccn.org/profesionnals/physician_gls/f_guidelines.asp.
- Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs.fluconazole orintraconazole prophylaxis in patients with neutropenia. N Eng J Med 2007; 356: 348–359.
- Lee JH, Lee KH, Lee JH, et al. Decreased incidence of febrile episodes with antibiotic prophyalxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res 2011; 35: 499–503.
- Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
- Greenberg P, Tuechler H, Schanz J, et al. Revised International prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.
- Okamoto T, Okada M, Mori A, et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 1997; 66: 345–351.
- Komrokji RS, Corrrales-Yepez M, kharfan-Dabaja MA, et al. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol 2012; 87: 1006–1009.
- Sevindik OG, Guc Z, Kahraman S, et al. Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities. Leuk Lymphoma 2015; 56: 2552–2555.